Previous Close | 1.81 |
1-Year Change | -23.95% |
6-Months Change | -14.22% |
3-Months Change | -14.62% |
Moving Avg (50d) | 2.4094 |
Moving Avg (200d) | 2.1957 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 202.5M |
Beta (3-Years) | 0.9 |
Revenue Growth (ttm) | 42.8% |
Net Profit Margin (ttm) | -202.51% |
Return On Assets (ttm) | -94.16% |
EPS (ttm) | -2.36 |
PE Ratio (ttm) | -0.77 |
Dividend Yield | % |
Asset Description: | Esperion Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
1.774 | 1.719 | 1.683 | 1.629 | 1.538 | 1.448 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.